Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Vitamin D aids in the absorption of calcium and has central roles in bone formation and maintenance, hypertension, cancer, and immunity. Vitamin D2 is produced in fungi, including yeast, from ergosterol in response to ultraviolet radiation. 25-hydroxy Vitamin D2 is an intermediate produced from vitamin D2 by cytochrome P450 isoforms in vertebrates. It is subsequently metabolized to 1,25-dihydroxy vitamin D2, which is an agonist for the vitamin D receptor.
25-hydroxy Vitamin D2 is supplied as a crystalline solid. A stock solution may be made by dissolving the 25-hydroxy vitamin D2 in the solvent of choice. 25-hydroxy Vitamin D2 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of 25-hydroxy vitamin D2 in these solvents is approximately 20 mg/ml. 25-hydroxy vitamin D2 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, 25-hydroxy vitamin D2 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. 25-hydroxy Vitamin D2 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 357(3), 266-281 (2007).
Peterlik, M., Boonen, S., Cross, H.S., et al. Vitamin D and calcium insufficiency-related chronic diseases: An emerging world-wide public health problem. Int. J. Environ. Res. Public Health 6, 2585-607 (2009).
Gravellone, L., Rizzo, M.A., Martina, V., et al. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Int. J. Nephrol. 2011, (2011).